Recombinant osteoprotegerin (Amgen)

重组骨保护素

Report date: 2024/01/25 09:17:47

Base Information

Drug NameRecombinant osteoprotegerin (Amgen)

Drug Alias NameOCIFOsteoclastogenesis Inhibiting FactorAMGN-0007AMG-0007OPG-Fc +[6]

ClassificationBiologics > Protein drugs > Recombinant protein

Mechanisms of ActionOsteoclasts inhibitorsTumor necrosis factor ligand superfamily member 11 inhibitors

TargetsTumor necrosis factor ligand superfamily member 11

Therapy Area/IndicationsCancer PainHyperparathyroidismArthritis, Rheumatoid +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAmgen Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesAmgen Inc

Active IndicationsN/A

Inactive IndicationsCancer PainHyperparathyroidismArthritis, Rheumatoid +[5]

ATC CodeN/A